Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Alexion Pharmaceuticals (United States) · Johns Hopkins University · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
762
total citations
- FWCI
- 7.68
- Percentile
- 100%
- References
- 88
Citations per year
Authors
5- RPRussell P. RotherCorresponding
Alexion Pharmaceuticals (United States)
- SAScott A. Rollins
Alexion Pharmaceuticals (United States)
- CFChristopher F. Mojcik
Alexion Pharmaceuticals (United States)
- RARobert A. Brodsky
Johns Hopkins University, Johns Hopkins Medicine
- LBLeonard Bell
Alexion Pharmaceuticals (United States)
Topics & keywords
Topics
Keywords
- Eculizumab
- Paroxysmal nocturnal hemoglobinuria
- Complement system
- CD59
- Immunology
- Complement component 5
- Complement deficiency
- Hemoglobinuria
No related works found for this paper.